- Details
- Charles Drake, a leader in the research of immunology in castration-resistant prostate cancer, (mCRPC) discusses the evolution of immunotherapy in prostate cancer. Together with Charles Ryan, in this discussion, he focuses on the best combination therapies and MSI-high disease in metastatic prostate cancer. Biographies: Charles G. Drake, MD, Ph.D., Department of Medicine, Division of Hematology/On...
|
- Details
- Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...
|
- Details
- Cora Sternberg joins Alicia Morgans and shares highlights from the Management of castration-resistant prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) and key takeaways from the session when thinking about managing these patients with this disease. She highlights Professor Michael Hofman's presentation on PSMA Targeted Therapies focusing on Lutetium PSMA sc...
|
- Details
- In this presentation, Robert Bristow speaks on the concept of local radiotherapy to the primary tumor in the metastatic prostate cancer setting at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Bristow's presentation covers the concept of oligometastatic disease, the rationale for treating the primary tumor, and the future role of metastases-directed therapy including differen...
|
- Details
- Charles Drake presented on immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) during the Management of Castration-resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He reviews several immunotherapy trials including the first major successful trial in immunotherapy for prostate cancer, the IMPACT trial in 2010 which led...
|
- Details
- Thomas Steuber spoke on the role of surgery in the setting of metastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He highlights the advantages of surgical removal of the primary tumor, the effects of surgery on cancer-specific survival and overall survival compared with no local treatment in the setting of de novo metastatic prostate cancer, and prospectiv...
|
- Details
- Jacob Berchuck, MD and Mary-Ellen Taplin, MD join Alicia Morgans in discussing areas of genetic risk in high-risk localized prostate cancer. They discuss the complexity of screening patients and incorporating the identifying of patients for genetic risk into clinical workflow. Jacob shares details on a collaboration with Mark Pomerantz at Dana-Farber and Phil Kantoff at Memorial Sloan Kettering, a...
|
- Details
- Susan Halabi provides an update on an externally validated prognostic model of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, which included eight important prognostic factors variables of overall survival: opioid analgesic use, ECOG performance status, albumin, disease site, LDH, hemoglobin, PSA, and alkaline phosphatase. They use...
|
- Details
- Oliver Sartor joins Charles Ryan in a discussion on a Phase 4 registry trial in men with metastatic castration-resistant prostate cancer (mCRPC). The IMPACT study analyses suggested that overall survival (OS) was longer in treated and control patients with low baseline PSA, and OS benefit was greatest for sipuleucel-T versus control in the patients with the lowest PSA (Schellhammer Urol 2013). Eli...
|
- Details
- Sipuleucel-T (Provenge ® ) has been FDA approved since 2010 in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). The IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment), was a randomized, double-blind, placebo-controlled study of 512 men with metastatic, hormone-refractory prostate cancer. Initially, the targeted patients were those wi...
|
